Methylphenidate Extended Release Oral Tablet [Concerta]
RxNorm 370331
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 370331 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: methylphenidate Extended Release Oral Tablet [Concerta].
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SBDFPrescribable
Semantic Branded Drug Form (SBDF):
Methylphenidate Extended Release Oral Tablet [Concerta]
(Atom ID: 12322919)
Patient Education
Methylphenidate
Methylphenidate is used as part of a treatment program to control symptoms of attention deficit hyperactivity disorder (ADHD; more difficulty focusing, controlling actions, and remaining still or quiet than other people who are the same age) in adults and children. Methylphenidate (Methylin) is also used to treat narcolepsy (a sleep disorder that causes excessive daytime sleepiness and sudden attacks of sleep). Methylphenidate is in a class of medications called central nervous system (CNS) stimulants. It works by changing the amounts of certain natural substances in the brain.
[Learn More]
* Please review the disclaimer below.